MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Rogers Sugar Inc. (RSI) will be holding a conference call to discuss their 2025 third quarter results on Tuesday, August 12, 2025, at 8:00 a.m. (Eastern Time). The conference call will be chaired by Mr. Michael Walton, Chief Executive Officer and Mr. Jean-Sébastien Couillard, Chief Financial Officer. If you wish to participate, please dial 1-800-717-1738. A recording of the conference call will be accessible shortly after the conference, by dialing 1-888-660-6264 ...

Core Insights - CG Oncology, Inc. reported positive results from the Phase 3 BOND-003 trial, highlighting the durability and tolerability of cretostimogene for bladder cancer treatment [2][6] - The company plans to submit a Biologics License Application (BLA) for cretostimogene in Q4 2025, targeting high-risk non-muscle invasive bladder cancer (NMIBC) patients unresponsive to BCG [2][11] - A recent legal victory against ANI Pharmaceuticals allows CG Oncology to focus resources on developing cretostimogene without future royalty obligations [2][5] Financial Highlights - For Q2 2025, CG Oncology reported a net loss of $41.4 million, or $0.54 per share, compared to a net loss of $18.9 million, or $0.28 per share in Q2 2024 [11][14] - Research and development expenses increased to $31.3 million in Q2 2025 from $18.5 million in Q2 2024, primarily due to higher clinical trial costs and increased headcount [11][14] - General and administrative expenses rose to $17.4 million in Q2 2025 from $7.5 million in Q2 2024, attributed to personnel-related costs and legal expenses [11][14] Cash Position - As of June 30, 2025, CG Oncology had cash and cash equivalents of $661.1 million, down from $688.4 million as of March 31, 2025 [11][16] - The company expects its current cash position to fund operations into the first half of 2028 [11] Clinical Development Updates - The company presented best-in-disease durability data from the BOND-003 trial, showing a 75.5% complete response rate at any time and a median duration of response of 28 months [6] - The CORE-008 trial was initiated to evaluate the combination of cretostimogene and gemcitabine in high-risk BCG-exposed NMIBC patients [5][6] - Anticipated milestones include the completion of Phase 3 enrollment for PIVOT-006 in Q3 2025 and topline data from various trials expected in Q4 2025 and 1H 2026 [4][11]

Core Insights - Gauzy Ltd. announced the election of Alejandro Weinstein to its Board of Directors, effective November 1, 2025, following the annual general meeting of shareholders [1] - The company aims to adopt a leaner board structure to reduce corporate expenses and maintain agility [1] Company Leadership - Alejandro Weinstein has over 30 years of managerial experience, including serving as CEO of CFR Pharmaceuticals S.A., where he led the company to a multi-billion-dollar sale to Abbott Laboratories [2] - His expertise in global expansion, mergers and acquisitions, and public company leadership is expected to support Gauzy's growth and strategic objectives [2][3] Board Changes - Gal Gitter concluded his service on the Board after his term expired, and Danny Allouche is also stepping down, both recognized for their significant contributions during their tenures [3] - Eyal Peso, CEO and Chairman of Gauzy, expressed gratitude for the contributions of both departing board members, highlighting their roles in the company's growth and strategic direction [3] Company Overview - Gauzy Ltd. specializes in vision and light control technologies, focusing on research, development, manufacturing, and marketing [4] - The company operates globally with subsidiaries in multiple countries, serving various industries including aeronautics, automotive, and architecture [4]

André Courville Photo of André Courville. MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces the appointment of Mr. André Courville as Chair of the Board of Directors. He will officially succeed Mr. Alain Rhéaume on September 30, following Mr. Rhéaume’s retirement announced last June after 15 years of service on the Board, including eight as Chair. Following the announcement of Mr. Rhéaume’s retirement, the Board’s Governance Committee diligently i ...

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025. HighlightsFinancial results Lower EBITDA(A)1, operating income and net earnings in Q2-2025: Production up 14% (10% on a Combined1 basis)2 from Q2-2024 owing to a strong performance by operating assets in North America and the contribution of newly commissioned sites in Europe. Production was nevertheless 2% (9%) below anticipated production1 du ...

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces that Bruno Guilmette, Executive Vice President and Chief Financial Officer, has chosen to take on new challenges by accepting a new professional opportunity, after nearly seven years with the Company. He will remain as Chief Financial Officer until September 12, 2025, to ensure a smooth transition. A respected leader, Bruno Guilmette has played a key role in Boralex’s financial evolution over the past ...

Company Overview - Ensurge Micropower ASA held an Extraordinary General Meeting where all agenda items were adopted, including the issuance of 20,000,000 warrants to investors from a private placement announced on 8 July 2025 [1] - The company is focused on developing ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbatteries [2] Technology and Innovation - Ensurge has a workforce of forty specialists based in Silicon Valley, developing innovative microbattery technology suitable for various applications such as hearables, wearables, and IoT sensor solutions [3] - The company's manufacturing facility utilizes patented process technology and materials innovation, optimized for prototyping and small-scale manufacturing, with plans to outsource production to specialized partners for scaling [4] Financial and Market Position - Ensurge is listed on the Norwegian stock exchange and is financed by strong financial investors, indicating a strategic investment and robust transatlantic collaboration [5]

Group 1 - First American Uranium Inc. will enter into a debt settlement agreement involving the issuance of 2,000,000 common shares at a deemed price of $0.205 per share, totaling $410,000 for services provided by creditors [1][2] - The debt settlement includes $73,500 owed to a Director and Officer of the Company [1] - All shares issued will be subject to a statutory hold period of four months plus a day from the date of issuance, pending necessary corporate and regulatory approvals [2] Group 2 - First American Uranium Inc. is focused on mineral exploration and acquisition of mineral property assets in North America, with an objective to develop economic precious and base metal properties [3] - The Company is conducting exploration programs on the Silver Lake property, located approximately 30 km southeast of Houston, British Columbia [3]

HOUSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported solid second-quarter 2025 results and provided the following highlights: Second-Quarter Results Reported net income attributable to PAA of $210 million and net cash provided by operating activities of $694 millionDelivered Adjusted EBITDA attributable to PAA of $672 millionExited the quarter with 3.3x leverage ratio, toward the low-end of our target range of 3.25x ...

Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 ne ...